Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062658 · ClinicalTrials.gov registry record · Phase 2
Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02062658 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 10 participants.
The verdict
NCT02062658, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called Exposure and Response Prevention (EX/RP). You will be compensated for your time and travel. Participants must be between the ages of 18-55.
Interventions
- DRUG Ketamine
- BEHAVIORAL Exposure and Response Prevention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02062658
The ClinicalTrials.gov registry entry for NCT02062658 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT02062658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02062658 about?
NCT02062658 is a clinical study titled "Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)". This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called Exposure and Response Prevention (EX/RP). You will be compensat...
What is the current status of trial NCT02062658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02062658?
The interventions under investigation include: Ketamine (DRUG), Exposure and Response Prevention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02062658?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.